TL;DR
Picking a cancer drug usually means trying one on the patient and watching what happens. A Paris start-up called Orakl Oncology is trying to run that experiment in a dish first. The details, the numbers and our odds on what comes next are below the line. Subscribe to read them.
A story we are following. Computer copies of patients, sometimes called digital patients, could shorten the wait for nearly every new medicine, so we track each step toward them.
Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our labeled speculation on what it adds up to; and every source.



